Overview
- Editors:
-
-
Alan Cowan
-
Department of Pharmacology Center for Substance Abuse Research, Temple University School of Medicine, Philadelphia, USA
-
Gil Yosipovitch
-
Department of Dermatology, Temple University School of Medicine, Philadephia, USA
- Provides insights into contemporary treatment regimens for pruritus in different human scenarios
- Information on the multiple pathways for itch and their interactions with pain
- Most recent results of research in the field
Access this book
Other ways to access
Table of contents (19 chapters)
-
Front Matter
Pages i-viii
-
- Elke Weisshaar, Wolfgang U. Eckart, Jeffrey D. Bernhard
Pages 1-14
-
- Brittany Leader, Christopher W. Carr, Suephy C. Chen
Pages 15-38
-
-
- Gil Yosipovitch, Hideki Mochizuki
Pages 57-70
-
-
- Balázs I. Tóth, Arpad Szallasi, Tamás BÃró
Pages 89-133
-
-
- Santosh K. Mishra, Mark A. Hoon
Pages 151-162
-
- Eoin R. Storan, Susan M. O’Gorman, Ian D. McDonald, Martin Steinhoff
Pages 163-176
-
- Jamie Schwendinger-Schreck, Sarah R. Wilson, Diana M. Bautista
Pages 177-190
-
- Lindsey M. Snyder, Sarah E. Ross
Pages 191-206
-
-
- Tasuku Akiyama, Ethan A. Lerner, E. Carstens
Pages 219-235
-
- Sonja Ständer, Thomas A. Luger
Pages 237-255
-
- Robin L. Thurmond, Kayvan Kazerouni, Sandra R. Chaplan, Andrew J. Greenspan
Pages 257-290
-
- Alan Cowan, George B. Kehner, Saadet Inan
Pages 291-314
-
-
- Tabi Anika Leslie, Malcolm W. Greaves, Gil Yosipovitch
Pages 337-356
-
- Thierry Olivry, Wolfgang Bäumer
Pages 357-369
About this book
Basic research on the pharmacology of itch has exploded in the wake of two very influential papers that were published in Nature (2007) and Science (2009). Long overlooked as a milder form of pain, itching has rapidly gained a new appreciation in both research and clinical communities because of its complexity and its negative effects on the quality of life of the distressed patients. Like pain, not all itches are the same. Unlike pain, there are no standard drugs equivalent to aspirin and morphine. Epidemiological studies emphasize the high incidence and economic costs of itch (pruritus). It is the most prevalent symptom of a wide variety of allergic and inflammatory skin conditions (e.g., psoriasis, atopic dermatitis), is associated with several systemic diseases (e.g., chronic kidney and liver disease), and occurs in patients undergoing hemodialysis, spinal administration of opioids, and in those suffering from AIDS. The reader will learn about the multiple pathways for itch and their interactions with pain. The relationship between these closely related, yet distinct sensory phenomena, will be emphasized. Both itch and pain use several common molecules to send signals to the brain. Thus, drugs that have been, and are being, developed as analgesics may also attenuate intractable itch. This has been an exciting and very necessary turn of events since traditional H-1 receptor antagonists are ineffective in blocking the pruritus associated with kidney failure and cholestasis. The clinical chapters will provide insights into contemporary treatment regimens for pruritus in different human scenarios.
Editors and Affiliations
-
Department of Pharmacology Center for Substance Abuse Research, Temple University School of Medicine, Philadelphia, USA
Alan Cowan
-
Department of Dermatology, Temple University School of Medicine, Philadephia, USA
Gil Yosipovitch